Recombinant human RET/PTC2, the fusion protein [PRKAR1A (1-236)-RET (713-end)], was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.
Catalog No. R02-19CG
Catalog No. | Pack Size | Price (USD) | |
---|---|---|---|
R02-19CG-05 | 5 ug | $259 | |
R02-19CG-10 | 10 ug | $380 | |
R02-19CG-BULK | BULK | Contact Us |
Overview:
RET/PTC2 is fused of the tyrosine-kinase domain of proto-RET with the regulatory subunit R/A of c-AMP-dependent protein kinase A, by transforming a chromosomal translocation at t(10;17)(q11.2;q23) (1). The RET/PTC oncoproteins display constitutive TK activity and tyrosine phosphorylation. The RET/PTC2 Tyr-539 is an essential docking site for activating the SH2-containing transducer phospholipase PLCgamma (2). The RET/PTC2 activation may play crucial roles in papillary thyroid tumorigenesis and neoplastic oncogene.
Gene Aliases:
PRKAR1A: CAR; CNC; CNC1; PKR1; PPNAD1; PRKAR1; TSE1 RET: CDHF12, RET51, PTC, RET-ELE1; RET/PTC2
References:
1. Gabriella S. et al: A t( 10; 17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma. Genes, Chromosomes and Cancer. 9:244-250 (1994).
2. M G Borrello, et al: The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Mol Cell Biol. May 1996; 16(5): 2151–2163.
Specific Activity:
Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.
Purity:
Sample Purity Data. For specific information on a given lot, see related technical data sheet.
Storage, Stability and Shipping:
Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Molecular Weight:
~105 kDa
There are no related publications available for this product.
Cancer, Cell Cycle, Cellular Stress, Metabolic Disorder, Neurobiology
STAY CONNECTED
Fax: 1-604-232-4601